Literature DB >> 28122858

Target regimen profiles for treatment of tuberculosis: a WHO document.

Christian Lienhardt1, Payam Nahid2, Michael L Rich3,4,5, Cathy Bansbach6, Emily A Kendall7, Gavin Churchyard8,9, Lice González-Angulo10, Lia D'Ambrosio11, Giovanni Battista Migliori11, Mario Raviglione10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28122858      PMCID： PMC5509341          DOI： 10.1183/13993003.02352-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  31 in total

1.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

Authors:  Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

2.  Principles for designing future regimens for multidrug-resistant tuberculosis.

Authors:  Grania Brigden; Bern-Thomas Nyang'wa; Philipp du Cros; Francis Varaine; Jennifer Hughes; Michael Rich; C Robert Horsburgh; Carole D Mitnick; Eric Nuermberger; Helen McIlleron; Patrick P J Phillips; Manica Balasegaram
Journal:  Bull World Health Organ       Date:  2013-10-25       Impact factor: 9.408

3.  Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients.

Authors:  Jennifer Hughes; Petros Isaakidis; Aristomo Andries; Homa Mansoor; Vivian Cox; Graeme Meintjes; Helen Cox
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

Review 4.  New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.

Authors:  Christian Lienhardt; Mario Raviglione; Mel Spigelman; Richard Hafner; Ernesto Jaramillo; Michael Hoelscher; Alimuddin Zumla; Jan Gheuens
Journal:  J Infect Dis       Date:  2012-03-22       Impact factor: 5.226

5.  Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Authors:  Simon Tiberi; Marie-Christine Payen; Giovanni Sotgiu; Lia D'Ambrosio; Valentina Alarcon Guizado; Jan Willem Alffenaar; Marcos Abdo Arbex; Jose A Caminero; Rosella Centis; Saverio De Lorenzo; Mina Gaga; Gina Gualano; Aurora Jazmín Roby Arias; Anna Scardigli; Alena Skrahina; Ivan Solovic; Giorgia Sulis; Marina Tadolini; Onno W Akkerman; Edith Alarcon Arrascue; Alena Aleska; Vera Avchinko; Eduardo Henrique Bonini; Félix Antonio Chong Marín; Lorena Collahuazo López; Gerard de Vries; Simone Dore; Heinke Kunst; Alberto Matteelli; Charalampos Moschos; Fabrizio Palmieri; Apostolos Papavasileiou; Antonio Spanevello; Dante Vargas Vasquez; Pietro Viggiani; Veronica White; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2016-03-10       Impact factor: 16.671

Review 6.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Authors:  Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Jan-William C Alffenaar; Holly A Anger; Jose A Caminero; Paolo Castiglia; Saverio De Lorenzo; Giovanni Ferrara; Won-Jung Koh; Giesela F Schecter; Tae S Shim; Rupak Singla; Alena Skrahina; Antonio Spanevello; Zarir F Udwadia; Miquel Villar; Elisabetta Zampogna; Jean-Pierre Zellweger; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-04-10       Impact factor: 16.671

Review 7.  Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.

Authors:  Alimuddin Zumla; Jeremiah Chakaya; Rosella Centis; Lia D'Ambrosio; Peter Mwaba; Matthew Bates; Nathan Kapata; Thomas Nyirenda; Duncan Chanda; Sayoki Mfinanga; Michael Hoelscher; Markus Maeurer; Giovanni Battista Migliori
Journal:  Lancet Respir Med       Date:  2015-03-09       Impact factor: 30.700

Review 8.  Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.

Authors:  Nicholas Winters; Guillaume Butler-Laporte; Dick Menzies
Journal:  Eur Respir J       Date:  2015-09-17       Impact factor: 16.671

9.  Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Authors:  Alexander S Pym; Andreas H Diacon; Shen-Jie Tang; Francesca Conradie; Manfred Danilovits; Charoen Chuchottaworn; Irina Vasilyeva; Koen Andries; Nyasha Bakare; Tine De Marez; Myriam Haxaire-Theeuwes; Nacer Lounis; Paul Meyvisch; Ben Van Baelen; Rolf P G van Heeswijk; Brian Dannemann
Journal:  Eur Respir J       Date:  2015-12-02       Impact factor: 16.671

10.  Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.

Authors:  Jingtao Gao; Yan Ma; Jian Du; Guofeng Zhu; Shouyong Tan; Yanyong Fu; Liping Ma; Lianying Zhang; Feiying Liu; Daiyu Hu; Yanling Zhang; Xiangqun Li; Liang Li; Qi Li
Journal:  BMC Pulm Med       Date:  2016-02-04       Impact factor: 3.317
View more
  10 in total

1.  Drug-resistant tuberculosis in 2017: at a crossroads.

Authors:  David W Dowdy; Grant Theron; Jeffrey A Tornheim; Emily A Kendall
Journal:  Lancet Respir Med       Date:  2017-03-15       Impact factor: 30.700

2.  Pharmacodynamics and Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.

Authors:  Michael A Lyons
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

Review 3.  Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Authors:  Giovanni Battista Migliori; Emanuele Pontali; Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Simon Tiberi; Marina Tadolini; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2017-02-07       Impact factor: 5.923

4.  Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.

Authors:  Geraint Davies; Martin Boeree; Dave Hermann; Michael Hoelscher
Journal:  PLoS Med       Date:  2019-07-09       Impact factor: 11.069

5.  WHO target product profiles for TB preventive treatment.

Authors:  S Den Boon; C Lienhardt; M Zignol; K Schwartzman; N Arinaminpathy; J R Campbell; P Nahid; M Penazzato; D Menzies; J F Vesga; O Oxlade; G Churchyard; C S Merle; T Kasaeva; D Falzon
Journal:  Int J Tuberc Lung Dis       Date:  2022-04-01       Impact factor: 3.427

6.  Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design.

Authors:  Michael A Lyons
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-02-13

7.  Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study.

Authors:  Helen Cox; Zubeida Salaam-Dreyer; Galo A Goig; Mark P Nicol; Fabrizio Menardo; Anzaan Dippenaar; Erika Mohr-Holland; Johnny Daniels; Patrick G T Cudahy; Sonia Borrell; Miriam Reinhard; Anna Doetsch; Christian Beisel; Anja Reuter; Jennifer Furin; Sebastien Gagneux; Robin M Warren
Journal:  Lancet Microbe       Date:  2021-11

8.  A Case Report and Literature Review of the Outcome of Linezolid-Induced Optic and Peripheral Neuropathy in Patients With Multidrug-Resistant Pulmonary TB.

Authors:  Safia Bano; Ahmad Nawaz; Ahsan Numan; Muhammad Aarish Hassan; Muhammad Bilal Ahmad Shafique
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

9.  Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.

Authors:  Emily A Kendall; Shelly Malhotra; Sarah Cook-Scalise; Claudia M Denkinger; David W Dowdy
Journal:  BMC Infect Dis       Date:  2019-09-09       Impact factor: 3.090

Review 10.  Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.

Authors:  Christian Lienhardt; Andrew A Vernon; Marco Cavaleri; Sumati Nambiar; Payam Nahid
Journal:  PLoS Med       Date:  2019-09-06       Impact factor: 11.069
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.